Answers are grounded in this paper and cite their sources.
Metabolic syndrome consists of a group of diseases including hyperglycemia, dyslipidemia, hypertension, obesity, and insulin resistance.These disorders have been increasing progressively in recent years, and there is a need for rapid and effective therapeutic solutions to overcome the global and economic burden.Phytomedicines are secondary metabolites present in plants, which are excellent and potential therapeutic agents in the management of metabolic diseases with higher safety profiles and lesser adverse effects.Antioxidant, antihypertensive, hypoglycemic, antitumor, anti-inflammatory, and insulin-producing are the important properties of phytochemicals.Limited biostability and bioavailability are the major drawback for the application of phytomedicine for the prevention of metabolic diseases.Nano-phytomedicines have a promising future for strengthening the efficacy of therapeutic plants by increasing their biocompatibility, biostability, biodegradability, and targeted delivery in metabolic disorders.Nano-based formulations of phytomedicines have a significant advantage including enhancement of pharmacological activity, bioavailability, solubility, stability, and safeguarding from toxicity.Nanosized phytomedicines like curcumin, oleoresin capsicum, berberine, naringenin, quercetin, glycemic acid, scutellarin, resveratrol, silybin, myricitrin, stevioside, alpha-eleostearic acid, etc. show better therapeutics for the treatment of metabolic disorders.These phytochemicals-based Nanoparticles (NPs) were mainly formulated in form of inorganic NPs, polymeric NPs, solid-lipid NPs, nanoemulsions, colloidal nanoliposome, and quantum dots.Nonetheless, with a rising incidence, metabolic diseases are one of the major worldwide health issues and preventing/ treating them by nanomaterial intervention of phytochemicals might be a possible strategy for improving the effectiveness of herbal plants for the treatment and management of various metabolic disorders.
No takes yet. Share an insight, caveat, or question.
Radhika et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: